Literature DB >> 28357065

Role of microRNAs in the pathogenesis of diabetic cardiomyopathy.

Xinyu Liu1, Shixue Liu2.   

Abstract

The morbidity of diabetes mellitus has been increasing annually. As a progressive metabolic disorder, chronic complications occur in the late stage of diabetes. In addition, cardiovascular diseases account for the major cause of morbidity and mortality among the diabetic population worldwide. Diabetic cardiomyopathy (DCM) is a type of diabetic heart disease. Patients with DCM show symptoms and signs of heart failure while no specific cause, such as coronary disease, hypertension, alcohol consumption, or other structural heart diseases has been identified. The pathogenesis of DCM is complex and has not been well understood until recently. MicroRNAs (miRs) belong to a novel family of highly conserved, short, non-coding, single-stranded RNA molecules that regulate transcriptional and post-transcriptional gene expression. Furthermore, recent studies have demonstrated an association between miRs and DCM. In the current review, the role of miRs in the pathogenesis of DCM is summarized. It was concluded that miRs contribute to the regulation of cardiomyocyte hypertrophy, myocardial fibrosis, cardiomyocyte apoptosis, mitochondrial dysfunction, myocardial electrical remodeling, epigenetic modification and various other pathophysiological processes of DCM. These studies may provide novel insights into targets for prevention and treatment of the disease.

Entities:  

Keywords:  diabetic cardiomyopathy; miRNA

Year:  2017        PMID: 28357065      PMCID: PMC5351040          DOI: 10.3892/br.2017.841

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  47 in total

1.  MicroRNA-451 exacerbates lipotoxicity in cardiac myocytes and high-fat diet-induced cardiac hypertrophy in mice through suppression of the LKB1/AMPK pathway.

Authors:  Yasuhide Kuwabara; Takahiro Horie; Osamu Baba; Shin Watanabe; Masataka Nishiga; Shunsuke Usami; Masayasu Izuhara; Tetsushi Nakao; Tomohiro Nishino; Kinya Otsu; Toru Kita; Takeshi Kimura; Koh Ono
Journal:  Circ Res       Date:  2014-10-31       Impact factor: 17.367

Review 2.  Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?

Authors:  Stephan Fichtlscherer; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-11       Impact factor: 8.311

Review 3.  Diabetic cardiomyopathy: from pathophysiology to treatment.

Authors:  Konstantinos Trachanas; Skevos Sideris; Constantina Aggeli; Emmanouil Poulidakis; Konstantinos Gatzoulis; Dimitrios Tousoulis; Ioannis Kallikazaros
Journal:  Hellenic J Cardiol       Date:  2014 Sep-Oct

4.  Induction of autophagy markers is associated with attenuation of miR-133a in diabetic heart failure patients undergoing mechanical unloading.

Authors:  Shyam Sundar Nandi; Michael J Duryee; Hamid R Shahshahan; Geoffrey M Thiele; Daniel R Anderson; Paras K Mishra
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

5.  Inhibiting microRNA-144 abates oxidative stress and reduces apoptosis in hearts of streptozotocin-induced diabetic mice.

Authors:  Manli Yu; Yu Liu; Bili Zhang; Yicheng Shi; Ling Cui; Xianxian Zhao
Journal:  Cardiovasc Pathol       Date:  2015-06-19       Impact factor: 2.185

6.  miR-141 as a regulator of the mitochondrial phosphate carrier (Slc25a3) in the type 1 diabetic heart.

Authors:  Walter A Baseler; Dharendra Thapa; Rajaganapathi Jagannathan; Erinne R Dabkowski; Tara L Croston; John M Hollander
Journal:  Am J Physiol Cell Physiol       Date:  2012-10-03       Impact factor: 4.249

Review 7.  Role of epigenetic mechanisms in the development of chronic complications of diabetes.

Authors:  Malgorzata Wegner; Daniel Neddermann; Maria Piorunska-Stolzmann; Pawel P Jagodzinski
Journal:  Diabetes Res Clin Pract       Date:  2014-04-02       Impact factor: 5.602

8.  MicroRNA-133a regulates DNA methylation in diabetic cardiomyocytes.

Authors:  Vishalakshi Chavali; Suresh C Tyagi; Paras K Mishra
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.575

Review 9.  Emerging role of epigenetics and miRNA in diabetic cardiomyopathy.

Authors:  Mohamed Asrih; Sabine Steffens
Journal:  Cardiovasc Pathol       Date:  2012-08-28       Impact factor: 2.185

10.  MicroRNAs in diabetic cardiomyopathy and clinical perspectives.

Authors:  Qiulian Zhou; Dongchao Lv; Ping Chen; Tianzhao Xu; Siyi Fu; Jin Li; Yihua Bei
Journal:  Front Genet       Date:  2014-06-25       Impact factor: 4.599

View more
  13 in total

1.  Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals.

Authors:  Ioanna Kokkinopoulou; Eirini Maratou; Panayota Mitrou; Eleni Boutati; Diamantis C Sideris; Emmanuel G Fragoulis; Maria-Ioanna Christodoulou
Journal:  Endocrine       Date:  2019-09-26       Impact factor: 3.633

Review 2.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

Review 3.  Epigenetic signatures in cardiac fibrosis, special emphasis on DNA methylation and histone modification.

Authors:  Hui Tao; Zheng-Yu Song; Xuan-Sheng Ding; Jing-Jing Yang; Kai-Hu Shi; Jun Li
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

Review 4.  Opportunities for microRNAs in the Crowded Field of Cardiovascular Biomarkers.

Authors:  Perry V Halushka; Andrew J Goodwin; Marc K Halushka
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

5.  MiR-144 affects proliferation and apoptosis of high glucose-induced AC16 cardiomyocytes by regulating CTRP3/JNK signaling.

Authors:  Yanling Song; Huade Mai; Yunyun Lin; Yachun Wang; Xiaoxi Wang; Shenhong Gu
Journal:  Int J Clin Exp Pathol       Date:  2020-02-01

Review 6.  Emerging Evidence of Epigenetic Modifications in Vascular Complication of Diabetes.

Authors:  Madhu Khullar; Balneek Singh Cheema; Satish K Raut
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-29       Impact factor: 5.555

7.  Inhibition of long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 attenuates high glucose-induced cardiomyocyte apoptosis via regulation of miR-181a-5p.

Authors:  Yongxia Cheng; Jingchao Li; Chong Wang; Heran Yang; Ying Wang; Tao Zhan; Sufen Guo; Jun Liang; Yuxin Bai; Jianbo Yu; Guibo Liu
Journal:  Exp Anim       Date:  2019-07-29

8.  Role of MicroRNA-34a in Anti-Apoptotic Effects of Granulocyte-Colony Stimulating Factor in Diabetic Cardiomyopathy.

Authors:  In Hwa Park; Yi Sun Song; Hyun Woo Joo; Guang Yin Shen; Jin Hee Seong; Na Kyoung Shin; Young Jong Cho; Yonggu Lee; Jeong Hun Shin; Young Hyo Lim; Hyuck Kim; Kyung Soo Kim
Journal:  Diabetes Metab J       Date:  2019-04-23       Impact factor: 5.376

9.  Isolated downregulation of HCN2 in ventricles of rats with streptozotocin-induced diabetic cardiomyopathy.

Authors:  Katarina Hadova; Eva Kralova; Gabriel Doka; Lenka Bies Pivackova; Zuzana Kmecova; Peter Krenek; Jan Klimas
Journal:  BMC Cardiovasc Disord       Date:  2021-03-02       Impact factor: 2.298

10.  Inhibition of miR-186-5p contributes to high glucose-induced injury in AC16 cardiomyocytes.

Authors:  Jiamei Jiang; Hailiang Mo; Chang Liu; Bin Wu; Zijun Wu; Xingyue Li; Teng Li; Songjian He; Shanghai Li; Qiong You; Keng Wu; Runmin Guo
Journal:  Exp Ther Med       Date:  2017-11-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.